Table 2.
Baseline Lung Function | Mild | N | Moderate | N | Severe | N | P value* |
---|---|---|---|---|---|---|---|
FEV1% predicted | 94 ± 11 | 164 | 66 ± 11 | 70 | 62 ± 22 | 204 | <0.0001 |
FVC % predicted | 100 ± 12 | 81 ± 13 | 77 ± 20 | <0.0001 | |||
FEV1/FVC (%) | 80 ± 7 | 67 ± 10 | 65 ± 13 | <0.0001 | |||
Best lung function | 157 | 60 | 185 | ||||
FEV1% predicted | 102 ± 11 | 79 ± 12 | 77 ± 21 | <0.0001 | |||
FVC % predicted | 103 ± 13 | 91 ± 14 | 91 ± 18 | <0.0001 | |||
Maximal % change in FEV1 | 9 ± 7 | 20 ± 16 | 20 ± 24 | <0.0001 | |||
Methacholine PC 20 (log mg/mL) | 0.24 ± 0.62 | 133 | −0.11 ± 0.54 | 46 | −0.06 ± 0.7 | 87 | 0.002 |
Three way comparison, significant because of differences between mild vs. moderate and severe The magnitude of bronchodilator reversibility (9% vs. 20% and 20%, for mild vs. moderate and severe, respectively) correlated with the level of FEV1% predicted, P <0.0001 (94% vs. 66% and 62% for mild vs. moderate and severe, respectively) but not with disease severity classification (mild, moderate or severe).